Table 1.
Clinicopathologic characteristics of the cohort of endometrial cancer (EC).
| Feature | Low/Intermediate Risk n = 24 | High Risk n = 36 |
Total n = 60 |
|---|---|---|---|
| AGE (38–88 y/o*) | |||
| <66 y/o | 10 (41.67%) | 14 (38.89%) | 24 (40.00%) |
| ≥66 y/o | 14 (58.33%) | 22 (61.11%) | 36 (60.00%) |
| Time of diagnosis | |||
| Recently diagnosed | 22 (91.67%) | 31 (86.11%) | 53 (88.33%) |
| Recurrence | 2 (8.33%) | 5 (13.88%) | 7 (11.66%) |
| Histology | |||
| Endometrioid | 24 (100.00%) | 19 (52.78%) | 43 (71.67%) |
| Non-endometrioid | 0 (0.00%) | 17 (47.22%) | 17 (28.33%) |
| Histologic grade | |||
| Grade 1 | 15 (62.50%) | 5 (13.89%) | 20 (33.33%) |
| Grade 2 | 8 (33.33%) | 7 (19.44%) | 15 (41.66%) |
| Grade 3 | 1 (4.17%) | 24 (66.66%) | 25 (69.44%) |
| Figo stage | |||
| I | 23 (95.83% | 13 (36.11%) | 36 (60.00%) |
| II | 1 (4.17%) | 9 (25.00%) | 10 (16.67%) |
| III | 0 (0.00%) | 11 (30.56%) | 11 (18.33%) |
| IV | 0 (0.00%) | 3 (8.33%) | 3 (5.00%) |
| Myometrial invasion | |||
| <50% | 15 (62.50%) | 10 (27.78%) | 25 (41.67%) |
| ≥50% | 9 (37.50%) | 25 (69.44%) | 34 (56.67%) |
| Unknown | 0 (0.00%) | 1 (2.78%) | 1 (1.67%) |
| LVSI** | |||
| No | 13 (54.17%) | 18 (50.00%) | 31 (51.67%) |
| Yes | 3 (12.50%) | 11 (30.56%) | 14 (23.33%) |
| Unknown | 8 (33.33%) | 7 (19.44%) | 15 (25.00%) |
* y/o: years old; ** LVSI: lympho-vascular space involvement.